Sequential HER2 Blockade as Effective Therapy in Chemorefractory, HER2 Gene-Amplified, RAS Wild-Type, Metastatic Colorectal Cancer: Learning From a Clinical Case

ESMO Open - United Kingdom
doi 10.1136/esmoopen-2017-000299
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2016English

Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer

Clinical Cancer Research
Cancer ResearchOncology
2019English

HER2-Orientated Therapy in Early and Metastatic Breast Cancer

Breast Care
SurgeryOncology
2016English

HER2 Gene Copy Number Status May Influence Clinical Efficacy to Anti-Egfr Monoclonal Antibodies in Metastatic Colorectal Cancer Patients

British Journal of Cancer
Cancer ResearchOncology
2013English

HER2 Positivity Predicts Unresponsiveness to EGFR‐Targeted Treatment in Metastatic Colorectal Cancer

Oncologist
Cancer ResearchMedicineOncology
2019English

Retrospective Analysis of HER2 Therapy Interruption in Patients Responding to the Treatment in Metastatic HER2+ Breast Cancer

ESMO Open
Cancer ResearchOncology
2017English

Dual HER2 Blockade: Preclinical and Clinical Data

Breast Cancer Research
Cancer ResearchOncology
2014English

A Central Role for HER3 in HER2-Amplified Breast Cancer: Implications for Targeted Therapy

Cancer Research
Cancer ResearchOncology
2008English

Her2/Neu Protein Expression in Colorectal Cancer

Journal of Evolution of Medical and Dental Sciences
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy